Resolve Therapeutics Obtains $5,800,000 Series B Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ecbc5abc-bd5d-498f-8ae7-67cb2fce6796&Preview=1 -
Date
11/1/2012 -
Company Name
Resolve Therapeutics -
Mailing Address
5400 Carillon Point Kirkland, WA 98033 -
Company Description
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of RSLV-125, its novel targeted biologic therapy. -
Website
http://www.resolvebio.com -
Transaction Type
Venture Equity -
Transaction Amount
$5,800,000 -
Transaction Round
Series B -
Proceeds Purposes
These funds give Resolve the necessary resources to advance our investigational lupus compound RSLV-132 into clinical trials, which we expect to start in mid-2013. -
M&A Terms
-
Venture Investor
New Science Ventures -
Venture Investor
WRF Capital -
Venture Investor
Easton Capital
